Business
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial
About this update from Aclarion, Inc.
[{"type":"text","content":"Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company’s recent momentum and value-creating priorities for 2026. The letter highlights Aclarion’s continued momentum in expanding adoption of its Nociscan platform, growing clinical evidence, and advancing reimbursement initiatives in both the United Kingdom and the United States. The update also highlights the company’s ongoing CLARITY clinical trial, expansion of commercial engagement with physicians and imaging centers, and its strong balance sheet supporting continued execution. “Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business,” said Brent Ness, Chief Executive Officer of Aclarion. “With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders.” The full CEO Shareholder Letter is available on the company’s website. For more News from Aclarion, please visit: Latest News To find a Nociscan center, view our site map here. For more information on Nociscan, please email: [email protected] About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians ...